Abiogen acquires EffRx to fortify bone disease portfolio
Pharmaceutical Technology
MAY 30, 2023
Bisphosphonates are drugs that slow the progression of bone loss. EffRx has received several European regulatory approvals for drugs in its portfolio. Alkindi is one of EffRx’s three marketed drugs. In Italy, Abiogen began distributing its bisphosphonates in 2014 and has since seen some successful drug approvals.
130 
Let's personalize your content